This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
SNRNP200 / U5 small nuclear ribonucleoprotein 200 kDa helicase · IHC design guide
Design Immunohistochemistry for SNRNP200
Plan SNRNP200 paraffin IHC around the observed nuclear tissue pattern (HPA tissue IHC). Start the catalog antibody at 2–5 μg/ml (datasheet: 2–5 μg/ml), and assess staining with a nuclear counterstain.
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
SNRNP200 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear staining in several cell types (HPA tissue IHC) | |
| Staining pattern | Nuclear staining across several cell types (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A04514-2) | |
| Positive control | Bronchus+4 more · see all | |
| Negative control | Adrenal gland+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections. (standard IHC practice; not target-specific) | |
| Caveat | Fallopian tube cilia show high signal; score nuclei separately (HPA tissue IHC) | |
| Regulation | No specific regulator reported (UniProt) | |
| Isoform / epitope | 2 isoforms; check epitope coverage (UniProt) |
Section 1
Recommended SNRNP200 IHC & IF Protocols
The catalog antibody protocol is paired with published chromogenic SNRNP200 IHC methods for human spinal cord, motor cortex, and prostate sections (PMC9083243; PMC7000340).
| Sample | Paraffin-embedded human diffuse large B cell lymphoma tissue; fixative not specified (datasheet A04514-2) |
| Fixation | Image fixative and duration unreported (datasheet A04514-2); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A04514-2); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A04514-2) |
| Primary antibody | Rabbit anti-SNRNP200, 2-5 μg/ml (datasheet A04514-2) |
| Primary incubation | Overnight at 4 °C (datasheet A04514-2) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet A04514-2) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | SNRNP200-positive staining in ciliated cells (cell body) of bronchus (HPA tissue IHC: High). HPA tissue profile: Nuclear expression in several different cell types. No signal in the no-primary control. |
💡Decision noteStart with the catalog antibody’s heat-mediated EDTA retrieval at pH 8.0 (datasheet A04514-2); consider pH 6 retrieval for the published neural-tissue method (PMC9083243).
Section 2
What Is the Expected SNRNP200 Staining Pattern?
SNRNP200 is a nuclear spliceosome protein with no transmembrane segment (UniProt O75643). In paraffin-section IHC, expect nuclear staining in several cell types, including bronchial ciliated cells, placental trophoblastic cells and testicular seminiferous-duct cells reported as High (HPA tissue IHC). The tissue IHC assessment is Approved, with external verification pending (HPA antibody HPA029321).
| Distinct nuclear chromogen in bronchial ciliated cell bodies, with recognizable tissue structure. | This fits the reported nuclear profile and High staining in these cells (HPA tissue IHC). Judge the result by its nuclear location and the stained cell population; a dark deposit alone does not establish specific staining (general IHC practice). |
| Strong, widespread cytoplasmic or surface staining with little nuclear signal. | That is inconsistent with the dominant nuclear IHC profile (HPA tissue IHC; UniProt O75643). Review it as possible background or detection artefact (general IHC practice). HPA ICC-IF also reports uncertain cytosolic localization, so an isolated cytoplasmic signal is not definitive evidence either way (HPA subcellular). |
| Prominent staining in a cell population reported as Not detected, such as heart cardiomyocytes. | The result conflicts with that specific HPA tissue observation; it does not prove that every cardiomyocyte lacks SNRNP200 (HPA tissue IHC). Consider cross-reactivity or endogenous detection activity, then compare a negative reagent control and a known-positive cell population on the same run (general IHC practice). |
| Diffuse chromogen across nuclei, cytoplasm and tissue spaces, without clear cell boundaries. | This distribution cannot reliably be scored as nuclear SNRNP200 staining (HPA tissue IHC; general IHC practice). Examine background controls and tissue morphology before assigning intensity; diffuse deposition can obscure a genuine nuclear signal (general IHC practice). |
| No nuclear staining in an adequately represented, known-positive population, such as placental trophoblastic cells. | HPA reports High staining in those cells (HPA tissue IHC). Check that the expected cells are present, then review retrieval and detection controls as general IHC troubleshooting steps. A failed run cannot establish biological absence (general IHC practice). |
💡Expected SNRNP200 appearanceCall a result positive when chromogen is predominantly nuclear in an expected cell population, with High staining possible in bronchial ciliated cell bodies or placental trophoblastic cells (HPA tissue IHC); diffuse tissue-wide deposit or dominant nonnuclear signal warrants investigation (general IHC practice).
| Tissue and cell selection | Bronchial ciliated cell bodies, placental trophoblastic cells, seminiferous-duct cells and bladder urothelial cells are reported High; stomach glandular cells are Low (HPA tissue IHC). Compare like cell populations when interpreting intensity. These observations are examples, not a rule that every cell in each tissue stains equally (HPA tissue IHC). |
| Validation strength | The listed antibody, HPA029321, is Approved for IHC, with external verification pending (HPA antibody; HPA tissue IHC). Treat agreement with its reported pattern as supportive rather than conclusive. The supplied record does not assign it an Enhanced IHC validation status (HPA antibody). |
| Protein organization | SNRNP200 is nuclear, has no transmembrane segment, and has no signal peptide or propeptide reported (UniProt O75643). A membrane-dominant pattern would need independent confirmation. These features do not establish how formalin fixation or antigen retrieval affects its epitope (UniProt O75643). |
| Isoforms and antibody epitope | UniProt lists two isoforms (UniProt O75643). The supplied evidence gives no epitope position or isoform coverage for HPA029321, so do not attribute differing staining to an isoform or prescribe a target-specific retrieval condition from this record (HPA antibody; UniProt O75643). |
| IF/ICC Q: What localization should I expect? | A: Mainly nucleoplasmic staining is supported; cytosol and primary-cilium localization are marked uncertain (HPA subcellular). HPA also reports High staining in fallopian-tube cilia axonemes by tissue IHC (HPA tissue IHC). Assess any ciliary signal in its assay context; this IHC section supplies no IF/ICC protocol. |
| Situation | Likely cause | Next action |
|---|---|---|
| Known-positive cells have no visible nuclear chromogen. | The cause is unresolved; absent cells, an ineffective retrieval step or a failed detection step are possibilities (general IHC practice). | Confirm the expected cell population is present and inspect run controls before changing one IHC condition at a time (general IHC practice). Use an HPA High population as a reference, such as placental trophoblastic cells (HPA tissue IHC). |
| Most tissue areas look uniformly brown. | Nonspecific reagent binding or endogenous detection activity may produce background in chromogenic IHC (general IHC practice). | Compare a negative reagent control, check blocking and washing, and inspect whether chromogen follows cells or tissue spaces (general IHC practice). Score nuclear staining only where cell boundaries remain interpretable (HPA tissue IHC; general IHC practice). |
| Signal is mainly cytoplasmic, with weak or absent nuclear staining. | The distribution conflicts with the dominant nuclear pattern, although cytosolic localization is listed as uncertain in ICC-IF (HPA tissue IHC; HPA subcellular). | Check a nuclear positive population and a negative reagent control; review counterstain and morphology before calling cytoplasmic signal specific (general IHC practice). Do not use the uncertain ICC-IF location alone to validate IHC staining (HPA subcellular). |
| A reported Not detected population stains strongly. | Cross-reactivity or endogenous detection activity is possible; HPA's Not detected designation is an observation for that cell population (HPA tissue IHC; general IHC practice). | Verify cell identity, compare the negative reagent control, and assess an HPA High population in the same run (HPA tissue IHC; general IHC practice). Treat the discrepancy as unresolved until controls support an interpretation. |
| A low-staining tissue appears negative. | Low expression can be difficult to distinguish from background; stomach glandular cells are reported Low (HPA tissue IHC; general IHC practice). | First verify the run with an HPA High population, then score the low-staining cells against the negative reagent control (HPA tissue IHC; general IHC practice). Do not infer assay failure from a Low reference alone. |
| Prominent ciliary staining seems at odds with a nuclear result elsewhere. | HPA reports High fallopian-tube cilia-axoneme staining in tissue IHC, while its ICC-IF primary-cilium assignment is uncertain (HPA tissue IHC; HPA subcellular). | Record the tissue, cell compartment and assay separately; check controls and the accompanying nuclear pattern before assigning specificity (general IHC practice). The two HPA observations do not establish that every ciliary deposit is SNRNP200. |
Experiment evidence
IHC & IF images showing SNRNP200 staining
A04514-2 · IHCIHC analysis of SNRNP200 using anti-SNRNP200 antibody (A04514-2). SNRNP200 was detected in a paraffin-embedded section of human diffuse larg
A04514-2 · IHCIHC analysis of SNRNP200 using anti-SNRNP200 antibody (A04514-2). SNRNP200 was detected in a paraffin-embedded section of human duodenal pap
A04514-2 · IFIF analysis of SNRNP200 and Tubulin beta using anti-SNRNP200 antibody (A04514-2) and anti-Tubulin beta antibody (M05613-4). SNRNP200 and Tub
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000144028-SNRNP200/tissue/cerebral+cortex#imid_8016443
HPA · Oral mucosaHuman Protein Atlas IHC, Oral mucosa. Source: https://www.proteinatlas.org/ENSG00000144028-SNRNP200/tissue/oral+mucosa#imid_8016367
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000144028-SNRNP200/tissue/colon#imid_8016385
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000144028-SNRNP200/tissue/liver#imid_8016386
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA029321; green = SNRNP200, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA029321; green = SNRNP200, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for SNRNP200 IHC & IF
🧪Run bronchus first and assess staining in ciliated cells, which HPA rates High in the cell body (HPA: bronchus ciliated cells, High). Use heart muscle cardiomyocytes as a low-signal comparator (HPA: cardiomyocytes, Not detected); unstained neighboring cells on the bronchus slide can indicate background but should not be assumed target-negative (UniProt O75643: widely expressed).
Positive control tissue: Bronchus (Ciliated cells (cell body), HPA High)
Negative control tissue: Adrenal gland (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show SNRNP200 in A-431, U-251MG, U2OS, ASC52telo, RPTEC/TERT1, hTERT-RPE1 (serum starved), KOLF2.1J, with annotated localisation: Nucleoplasm (supported) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control and a concentration-matched rabbit isotype control, since the selected caption uses a rabbit primary antibody (selected-SKU tissue-IHC caption: rabbit anti-SNRNP200); use SNRNP200 knockout material as a biological specificity control (standard IHC practice). Block endogenous peroxidase and check for signal from bronchial inflammatory cells before interpreting DAB staining (standard chromogenic IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported in the supplied evidence, and the selected-SKU tissue-IHC caption does not state its fixative (selected-SKU tissue-IHC caption: fixative unreported). The reported paraffin-section example uses heat retrieval in EDTA at pH 8.0, but the evidence does not establish that retrieval is required for every specimen (selected-SKU tissue-IHC caption: EDTA retrieval). The supplied evidence does not establish whether frozen sections or IF are easier; interpret apparent ciliary signal cautiously because supported localization is nucleoplasmic, while primary-cilium localization is uncertain (HPA subcellular: nucleoplasm supported; primary cilium uncertain).
HPA tissue IHC evidence for SNRNP200
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Bronchus | Ciliated cells (cell body) | High | Protein (IHC) | HPA → |
| Fallopian tube | Ciliated cells (cilia axoneme) | High | Protein (IHC) | HPA → |
| Nasopharynx | Ciliated cells (cell body) | High | Protein (IHC) | HPA → |
| Placenta | Trophoblastic cells | High | Protein (IHC) | HPA → |
| Stomach | Glandular cells | Low | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Heart muscle | Cardiomyocytes | Not detected | Protein (IHC) | HPA → |
| Liver | Cholangiocytes | Not detected | Protein (IHC) | HPA → |
| Ovary | Ovarian stroma cells | Not detected | Protein (IHC) | HPA → |
| Parathyroid gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced SNRNP200 IHC Tips
Troubleshoot SNRNP200 staining by checking nuclear localisation, the documented retrieval conditions, and cell-level controls before interpreting chromogenic signal.
What retrieval conditions should I try when nuclear SNRNP200 staining is weak?
Start with heat-mediated antigen retrieval in EDTA, pH 8.0, for paraffin sections (datasheet A04514-2). The documented tissue example then used 2 μg/ml primary antibody overnight at 4°C, so match those conditions before changing several variables together (datasheet A04514-2). If nuclear staining remains weak, compare a carefully controlled alternative retrieval condition on adjacent sections while keeping antibody concentration and detection constant (standard IHC practice). Check tissue integrity and background after heating; excessive retrieval can make a stronger signal harder to interpret (standard IHC practice). Judge improvement by nuclear staining in intact cells, consistent with SNRNP200 localisation (UniProt O75643; HPA subcellular).
Could fixation explain weak or uneven SNRNP200 staining?
The selected paraffin-section caption does not report its fixative, so target-specific fixation sensitivity is unknown (datasheet A04514-2). Record the fixative, fixation duration, tissue thickness, and processing history for each specimen before comparing staining intensity (standard IHC practice). Compare adjacent sections processed together with the documented EDTA, pH 8.0 retrieval and 2 μg/ml primary incubation (datasheet A04514-2). Uneven fixation or processing can produce uneven immunostaining, but that possibility does not establish a SNRNP200-specific fixation effect (standard IHC practice). Evaluate intact tissue away from damaged edges and interpret any weak signal alongside matched controls (standard IHC practice).
Should I accept cytoplasmic or ciliary staining as SNRNP200 positive?
Prioritise nuclear staining: SNRNP200 is annotated as nuclear, and nucleoplasmic localisation has supporting subcellular evidence (UniProt O75643; HPA subcellular). HPA also lists cytosol and primary cilium as additional locations with uncertain support, so those patterns need independent confirmation (HPA subcellular). In paraffin sections, compare suspected extranuclear signal with neighbouring nuclei, a no-primary control, and the morphology of the stained cells (standard IHC practice). HPA reports high staining in ciliated cell bodies of bronchus and nasopharynx, and in fallopian-tube cilia axonemes; those are distinct observations (HPA tissue IHC). Do not score broad cytoplasmic haze as convincing localisation without reproducible cellular detail (standard IHC practice).
Can this stain distinguish SNRNP200 isoforms or phosphorylation states?
The record lists 2 SNRNP200 isoforms and several modified residues, including phosphoserines at 17, 26, and 225 (UniProt O75643). The supplied caption identifies the antibody and its tissue staining conditions but gives no epitope or isoform-specific validation (datasheet A04514-2). Therefore, interpret a nuclear signal as candidate SNRNP200 detection without assigning it to one isoform or phosphorylation state (UniProt O75643; datasheet A04514-2). Review the antibody's documented immunogen or epitope before comparing variants, and use separately validated reagents if that distinction drives the experiment (standard IHC practice). Keep retrieval and detection conditions matched across samples because accessibility changes can alter staining intensity (standard IHC practice).
How should I check SNRNP200 localisation in a multiplex IF experiment?
Use a marker for the expected cell type alongside SNRNP200, then assess whether its signal occupies the nucleus within those identified cells (UniProt O75643; HPA subcellular; standard IF practice). For ciliated epithelium, distinguish cell-body signal from any ciliary signal because HPA reports both patterns in different tissue entries (HPA tissue IHC). Choose spectrally separated fluorophores and assign the weaker signal to a channel with low tissue autofluorescence, confirmed by unstained controls (standard IF practice). SNRNP200 has no transmembrane segment and is mainly nucleoplasmic, so permeabilise fixed cells sufficiently to expose its intracellular epitope (UniProt O75643; HPA subcellular; standard IF practice). Optimise that step using directly relevant IF controls; the paraffin-section caption does not specify IF conditions (datasheet A04514-2).
How can I reduce diffuse brown staining without losing nuclear signal?
First compare the stained section with a no-primary control to identify secondary-reagent or detection background (standard IHC practice). The documented example used 10% goat serum blocking, a peroxidase-conjugated secondary, and DAB development (datasheet A04514-2). Include an endogenous peroxidase block in a chromogenic workflow and check whether DAB appears where nuclei are absent (standard IHC practice). If background persists, titrate the primary around the documented 2 μg/ml condition and keep retrieval at EDTA, pH 8.0 during that comparison (datasheet A04514-2; standard IHC practice). Prefer a condition that preserves defined nuclear staining over one that merely increases overall brown colour (UniProt O75643; standard IHC practice).
What should I score when comparing SNRNP200 across tissue sections? ⚠ ANSWER MARKED FOR VERIFICATION
Segment intact cells by morphology and counterstain, then score nuclear staining as the percentage of positive cells or an H-score (UniProt O75643; standard IHC practice). For an H-score, record the percentage at each intensity level and apply the same thresholds to every section (standard IHC practice). Normalise counts to the number of eligible cells in the same cell type, or report positive-cell density per mm² of evaluable tissue (standard IHC practice). Exclude folds, necrosis, and damaged edges using prespecified rules before analysis (standard IHC practice). Because HPA describes nuclear expression across several cell types, avoid treating a change in cell mixture as a change in per-cell SNRNP200 staining (HPA tissue IHC; standard IHC practice).
How do I distinguish true SNRNP200 staining from tissue artefact?
Convincing chromogenic signal should show reproducible nuclear detail in intact cells, consistent with SNRNP200's nuclear annotation and supported nucleoplasmic localisation (UniProt O75643; HPA subcellular). Interpret cell identity before calling a section negative: HPA reports high staining in urothelial cells but no detected staining in cardiomyocytes (HPA tissue IHC). Brown deposits limited to cut edges, folds, or necrotic areas warrant an artefact check rather than a positive call (standard IHC practice). Signal reproduced in a no-primary control may reflect endogenous enzyme activity or the detection system (standard IHC practice). Compare matched sections and controls before assigning biological meaning to weak extranuclear staining, whose additional localisation evidence is uncertain (HPA subcellular; standard IHC practice).
Boster reagents
Best SNRNP200 / U5 small nuclear ribonucleoprotein 200 kDa helicase IHC Antibodies
A04514-2 has IHC images from human paraffin sections and IF images from Caco-2 cells and a human paraffin section (catalog figure captions). Listed reactivity covers human, mouse, and rat (catalog).
Real IHC data
Anti-SNRNP200 Antibody ®
Cat # A04514-2
A04514-2 has IHC images from human diffuse large B cell lymphoma, duodenal papilla adenocarcinoma, endometrioid adenocarcinoma, and glioblastoma paraffin sections (A04514-2 IHC captions). It is also listed for IF, with images from Caco-2 cells and a human intestinal cancer paraffin section (A04514-2 applications; IF captions).
Which to pick: For tissue IHC, choose A04514-2: its own caption documents a human paraffin section, EDTA pH 8.0 retrieval, and 2 μg/ml primary antibody; the fixative is unreported (A04514-2 IHC caption). For IF/ICC, the same rabbit antibody is listed for IF and shown in cell and tissue images; clonality is unreported (A04514-2 catalog; IF captions). For mouse or rat samples, A04514-2 lists reactivity, while its supplied IHC images document human sections (A04514-2 catalog reactivity; IHC captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry O75643 (U520_HUMAN, U5 small nuclear ribonucleoprotein 200 kDa helicase).
- Human Protein Atlas. SNRNP200 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. SNRNP200 subcellular location (ICC-IF): Mainly localized to the nucleoplasm. In addition localized to the cytosol and primary cilium..
- Human Protein Atlas. SNRNP200 antibody validation summary (1 antibodies).
- Prognostic Significance of Elevated UCHL1, SNRNP200, and PAK4 Expression in High-Grade Clear Cell Renal Cell Carcinoma: Insights from LC-MS/MS Analysis and Immunohistochemical Validation. Cancers 2024 — PMC11352290.
- Defining the Caprin-1 Interactome in Unstressed and Stressed Conditions. Journal of proteome research 2021 — PMC9083243.
- Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer. EBioMedicine 2020 — PMC7000340.
- Targeting SNRNP200-induced splicing dysregulation offers an immunotherapy opportunity for glycolytic triple-negative breast cancer. Cell discovery 2024 — PMC11405407.
- PubMed PMID:16723661 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
- PubMed PMID:9872452 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for SNRNP200 (U5 small nuclear ribonucleoprotein 200 kDa helicase). Expected localisation Nuclear staining in several cell types (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A04514-2). Validated IHC antibody: A04514-2 at 2-5 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Bronchus (Ciliated cells (cell body)); negative Adrenal gland. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human diffuse large B cell lymphoma tissue; fixative not specified (datasheet A04514-2); 2. Fixation: Image fixative and duration unreported (datasheet A04514-2); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A04514-2); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A04514-2); 8. Primary antibody: Rabbit anti-SNRNP200, 2-5 μg/ml (datasheet A04514-2); 9. Primary incubation: Overnight at 4 °C (datasheet A04514-2). Watch for: Fixation: Keep fixation consistent across sections. (standard IHC practice; not target-specific); Caveat: Fallopian tube cilia show high signal; score nuclei separately (HPA tissue IHC); Isoform / epitope: 2 isoforms; check epitope coverage (UniProt); Regulation: No specific regulator reported (UniProt). Evidence: UniProt O75643, HPA tissue IHC · Approved, HPA ICC-IF · Mainly localized to the nucleoplasm. In addition localized to the…, Datasheet A04514-2, PMC9083243, PMC7000340. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/SNRNP200/immunohistochemistry-ihc-guide.